Blood, Vol. 114, Issue 16, 3448-3458, October 15, 2009

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Blood Figueroa et al. 114: 3448

Supplemental materials for: Figueroa et al

Files in this Data Supplement:

• Table S1. Patients’ characteristics (PDF, 16.5 KB)
  
  
• Table S2. Primers sequences for MassArray EpiTyper for technical validation of HELP assays (PDF, 51.4 KB)
  
  
• Table S3. Complete list of genes differentially methylated between MDS and Normal CD34⁺ controls (XLS, 965 KB)
  
  
• Table S4. Complete list of genes differentially methylated between de novo AML and Normal CD34⁺ controls (XLS, 86 KB)
  
  
• Figure S1. Technical validation of the HELP array findings using MassARRAY EpiTyper (JPG, 219 KB) -
  HELP methylation values (log HpaII/MspI ratios are represented in the x axis and percent methylation as measured by mass spectrophotometry of bisulfite-treated DNA is represented on the y axis.
  
  
  
  
  
  
• Figure S2. DNA methylation profiles are highly conserved between the CD34⁺ and CD34⁻ fractions of the bone marrow (JPG, 832 KB) -
  (A) Correlation matrix showing pair wise comparisons between the CD34⁺ and CD34⁻ cell fractions in three patients with MDS. (B) Correlation matrix showing pair wise comparisons between the CD34⁺ and CD34⁻ cell fractions in four healthy donors.
  
  
  
  
  
  
• Figure S3. WNT signaling genes are frequently methylated in MDS (JPG, 349 KB) -
  Heatmap representation of WNT signaling pathway genes found aberrantly methylated in MDS when compared to healthy donors. Cases are represented in the columns and genes in the rows.